Sarepta Therapeutics Stock Performance

SRPT Stock  USD 18.59  0.21  1.14%   
Sarepta Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 2.36, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sarepta Therapeutics will likely underperform. Sarepta Therapeutics right now has a risk of 4.21%. Please validate Sarepta Therapeutics downside variance, as well as the relationship between the daily balance of power and relative strength index , to decide if Sarepta Therapeutics will be following its existing price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sarepta Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Sarepta Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more

Actual Historical Performance (%)

One Day Return
1.14
Five Day Return
5.87
Year To Date Return
(12.76)
Ten Year Return
32.03
All Time Return
(52.33)
Last Split Factor
1:6
Last Split Date
2012-07-12
1
Insider Trading
11/21/2025
2
Disposition of tradable shares by Ryan Wong of Sarepta Therapeutics at 20.96 subject to Rule 16b-3
12/01/2025
3
Acquisition by Dallan Murray of 5500 shares of Sarepta Therapeutics subject to Rule 16b-3
12/12/2025
4
Disposition of 13187 shares by Ian Estepan of Sarepta Therapeutics at 22.31 subject to Rule 16b-3
12/16/2025
5
Assessing Sarepta Therapeutics Valuation After SRP-1005 Huntingtons Disease Trial Application
01/08/2026
6
Sarepta Therapeutics Now Covered by Barclays
01/28/2026
7
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntingtons Disease
02/04/2026
8
Is Sarepta Quietly Redefining Its Rare Disease Strategy With a Huntingtons Trial Bet
02/05/2026
9
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
02/11/2026
Begin Period Cash Flow444 M
Total Cashflows From Investing Activities755.6 M

Sarepta Therapeutics Relative Risk vs. Return Landscape

If you would invest  1,891  in Sarepta Therapeutics on November 22, 2025 and sell it today you would lose (32.00) from holding Sarepta Therapeutics or give up 1.69% of portfolio value over 90 days. Sarepta Therapeutics is currently generating 0.0599% in daily expected returns and assumes 4.2125% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Sarepta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Sarepta Therapeutics is expected to generate 1.79 times less return on investment than the market. In addition to that, the company is 5.61 times more volatile than its market benchmark. It trades about 0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of volatility.

Sarepta Therapeutics Target Price Odds to finish over Current Price

The tendency of Sarepta Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 18.59 90 days 18.59 
about 85.15
Based on a normal probability distribution, the odds of Sarepta Therapeutics to move above the current price in 90 days from now is about 85.15 (This Sarepta Therapeutics probability density function shows the probability of Sarepta Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.36 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Sarepta Therapeutics will likely underperform. Additionally Sarepta Therapeutics has an alpha of 0.0232, implying that it can generate a 0.0232 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Sarepta Therapeutics Price Density   
       Price  

Predictive Modules for Sarepta Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sarepta Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
14.2318.4422.65
Details
Intrinsic
Valuation
LowRealHigh
14.6318.8423.05
Details
Naive
Forecast
LowNextHigh
15.3419.5623.77
Details
26 Analysts
Consensus
LowTargetHigh
19.5121.4323.79
Details

Sarepta Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Sarepta Therapeutics is not an exception. The market had few large corrections towards the Sarepta Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sarepta Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sarepta Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.02
β
Beta against Dow Jones2.36
σ
Overall volatility
1.87
Ir
Information ratio 0.02

Sarepta Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sarepta Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sarepta Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sarepta Therapeutics had very high historical volatility over the last 90 days
Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Insider Trading

Sarepta Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sarepta Stock often depends not only on the future outlook of the current and potential Sarepta Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sarepta Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding107.9 M
Cash And Short Term Investments1.4 B

Sarepta Therapeutics Fundamentals Growth

Sarepta Stock prices reflect investors' perceptions of the future prospects and financial health of Sarepta Therapeutics, and Sarepta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sarepta Stock performance.

About Sarepta Therapeutics Performance

Assessing Sarepta Therapeutics' fundamental ratios provides investors with valuable insights into Sarepta Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sarepta Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 986.51  937.19 
Return On Tangible Assets 0.05  0.06 
Return On Capital Employed 0.08  0.08 
Return On Assets 0.05  0.06 
Return On Equity 0.14  0.15 

Things to note about Sarepta Therapeutics performance evaluation

Checking the ongoing alerts about Sarepta Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sarepta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sarepta Therapeutics had very high historical volatility over the last 90 days
Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Insider Trading
Evaluating Sarepta Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Sarepta Therapeutics' stock performance include:
  • Analyzing Sarepta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sarepta Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Sarepta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Sarepta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sarepta Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Sarepta Therapeutics' stock. These opinions can provide insight into Sarepta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Sarepta Therapeutics' stock performance is not an exact science, and many factors can impact Sarepta Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.